[go: up one dir, main page]

CY1111069T1 - Παραγωγα διυδροπυραζολοπυριμιδινονης - Google Patents

Παραγωγα διυδροπυραζολοπυριμιδινονης

Info

Publication number
CY1111069T1
CY1111069T1 CY20101100973T CY101100973T CY1111069T1 CY 1111069 T1 CY1111069 T1 CY 1111069T1 CY 20101100973 T CY20101100973 T CY 20101100973T CY 101100973 T CY101100973 T CY 101100973T CY 1111069 T1 CY1111069 T1 CY 1111069T1
Authority
CY
Cyprus
Prior art keywords
group
compounds
lower alkyl
alkyl group
dihydropyrazolopyrimidinone
Prior art date
Application number
CY20101100973T
Other languages
English (en)
Inventor
Toshihiro Sakamoto
Satoshi Sunami
Fuyuki Yamamoto
Kenji Niiyama
Makoto Bamba
Keiji Takahashi
Hidetomo Furuyama
Takeshi Sagara
Sachie Otsuki
Toshihide Nishibata
Takashi Yoshizumi
Hiroshi Hirai
Original Assignee
Banyu Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111069(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyu Pharmaceutical Co., Ltd. filed Critical Banyu Pharmaceutical Co., Ltd.
Publication of CY1111069T1 publication Critical patent/CY1111069T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η ευρεσιτεχνία αφορά ενώσεις γενικού τύπου (I): όπου το Α1 επιλέγεται από τον ακόλουθο τύπο (aa1)· το R1 είναι κατώτερη αλκελύν ομάδα ή κατώτερη αλκινύλ ομάδα· το R2 είναι φαινύλ, πυριδύλ ή θειενύλ ομάδα· το R5 και το R6 είναι άτομο υδρογόνου, κατώτερη αλκύλ ομάδα ή υδρόξυ κατώτερη αλκύλ ομάδα, κ.ο.κ. Οι ενώσεις της ευρεσιτεχνίας παρουσιάζουν εξαιρετική ανασταλτική δράση κινάσης Weel και ως εκ τούτου είναι χρήσιμες στο πεδίο των φαρμάκων ειδικά στη θεραπεία διαφόρων καρκίνων.
CY20101100973T 2006-04-27 2010-10-27 Παραγωγα διυδροπυραζολοπυριμιδινονης CY1111069T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27
PCT/JP2007/059408 WO2007126122A1 (en) 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinone derivatives

Publications (1)

Publication Number Publication Date
CY1111069T1 true CY1111069T1 (el) 2012-05-23

Family

ID=38655640

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100973T CY1111069T1 (el) 2006-04-27 2010-10-27 Παραγωγα διυδροπυραζολοπυριμιδινονης
CY20171100129T CY1118526T1 (el) 2006-04-27 2017-01-27 Παραγωγα διϋδροπυραζολοπυριμιδινονης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171100129T CY1118526T1 (el) 2006-04-27 2017-01-27 Παραγωγα διϋδροπυραζολοπυριμιδινονης

Country Status (39)

Country Link
US (4) US7935708B2 (el)
EP (2) EP2016080B1 (el)
JP (2) JP4513919B2 (el)
KR (1) KR101409161B1 (el)
CN (1) CN101432284B (el)
AR (1) AR060635A1 (el)
AT (1) ATE475662T1 (el)
AU (1) AU2007244185B2 (el)
BR (1) BRPI0710081A2 (el)
CA (1) CA2650119C (el)
CR (1) CR10359A (el)
CY (2) CY1111069T1 (el)
DE (1) DE602007008085D1 (el)
DK (2) DK2016080T3 (el)
DO (1) DOP2007000084A (el)
EC (1) ECSP088812A (el)
ES (2) ES2348751T3 (el)
GT (1) GT200800211A (el)
HK (1) HK1132498A1 (el)
HN (1) HN2008001532A (el)
HR (2) HRP20100563T1 (el)
HU (1) HUE032987T2 (el)
IL (1) IL194367A (el)
LT (1) LT2017278T (el)
MA (1) MA30428B1 (el)
MX (1) MX2008013063A (el)
MY (1) MY145408A (el)
NO (1) NO341617B1 (el)
NZ (1) NZ571196A (el)
PE (1) PE20080695A1 (el)
PL (2) PL2017278T3 (el)
PT (2) PT2016080E (el)
RU (1) RU2437885C2 (el)
SI (2) SI2016080T1 (el)
SV (1) SV2009003060A (el)
TW (1) TWI409262B (el)
UA (1) UA96152C2 (el)
WO (2) WO2007126122A1 (el)
ZA (1) ZA200807748B (el)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
WO2008133866A1 (en) * 2007-04-25 2008-11-06 Merck & Co., Inc. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
EP2213673B1 (en) * 2007-10-23 2013-06-05 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
US8507504B2 (en) 2008-06-12 2013-08-13 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
JP2012518598A (ja) * 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
EP2473633A4 (en) * 2009-09-02 2013-03-06 Msd Kk USE OF ONE OR MORE BIOMARKERS TO IDENTIFY A WEE1 DISEASED PATIENT AND PROCEDURE FOR TREATING CANCER MEDIATED BY DYSFUNCTIONAL OR ABERRANT P53 BY ADMINISTERING A WEE1 HEMMER
DK2477628T3 (en) 2009-09-15 2014-11-24 Merck Sharp & Dohme Preparation of crystalline hemihydratformer of dihydropyrazolopyrimidinon
CN103442710B (zh) 2010-11-16 2018-05-29 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
JP5979136B2 (ja) * 2011-04-27 2016-08-24 日本ゼオン株式会社 重合性化合物、重合性組成物、高分子、及び光学異方体
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CN104011049A (zh) 2011-10-20 2014-08-27 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
US9718821B2 (en) * 2012-02-23 2017-08-01 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
MX363243B (es) * 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
BR112015025852A2 (pt) 2013-04-09 2017-07-25 Lixte Biotechnology Inc as formulações de oxabicicloheptanos e oxabicicloheptenos
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
PL3235505T3 (pl) * 2014-12-17 2020-11-16 Delta-Fly Pharma, Inc. Kompozycja farmaceutyczna do leczenia lub opieki paliatywnej pacjenta w podeszłym wieku z nowotworem lub w ostatnim stadium nowotworu
TW201706258A (zh) 2015-04-17 2017-02-16 艾伯維有限公司 作為ｔｎｆ信號傳遞調節劑之吲唑酮
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
MX373865B (es) * 2015-09-01 2025-03-04 Taiho Pharmaceutical Co Ltd Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
CN106271589B (zh) * 2016-06-23 2018-12-28 中山市美捷时包装制品有限公司 一种用于预装阀杆、弹簧、垫片的组装设备
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
NZ750416A (en) 2016-09-15 2022-04-29 Boehringer Ingelheim Int Heteroaryl carboxamide compounds as inhibitors of ripk2
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
IL290857B2 (en) 2016-12-08 2023-03-01 Lixte Biotechnology Inc Oxabicycloheptanes for immune response modulation
WO2018133829A1 (zh) * 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
JP7140337B2 (ja) * 2017-03-23 2022-09-21 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド ピラゾロ［３，４－ｄ］ピリミジン－３－オンの大環状誘導体、その医薬組成物及び応用
EP3600247A1 (en) 2017-03-31 2020-02-05 Seattle Genetics, Inc. Combinations of chk1- and wee1 - inhibitors
SG11202000789WA (en) 2017-08-01 2020-02-27 Recurium Ip Holdings Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
US11613545B2 (en) * 2017-11-01 2023-03-28 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as Wee1 inhibitor and applications thereof
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN111315747B (zh) * 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en) 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
AU2019227823B2 (en) * 2018-02-28 2024-12-12 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
CN117720541A (zh) * 2018-03-09 2024-03-19 里科瑞尔姆Ip控股有限责任公司 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
US12180184B2 (en) 2018-10-26 2024-12-31 Wuxi Biocity Biopharmaceutics Co., Ltd. Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
KR102697799B1 (ko) 2019-03-22 2024-08-23 쇼우야오 홀딩스 (베이징) 코., 엘티디. Wee1 억제제 및 이의 제조 및 용도
US20220220115A1 (en) * 2019-04-09 2022-07-14 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
SMT202400303T1 (it) 2019-04-30 2024-09-16 Wuxi Biocity Biopharmaceutics Co Ltd Forma cristallina di un composto inibitore di wee1 e relativo uso
EP3992193A4 (en) * 2019-06-28 2023-08-16 Shanghai Pharmaceuticals Holding Co., Ltd. PYRAZOLOPYRIMIDINE COMPOUND, METHOD OF PRODUCTION THEREOF AND APPLICATIONS THEREOF
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
EP4048277A1 (en) 2019-10-25 2022-08-31 Astrazeneca AB Methods of treating cancer
BR112022012280A2 (pt) * 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN115698006B (zh) * 2020-06-17 2024-03-29 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物
KR102549484B1 (ko) * 2020-12-08 2023-06-29 한국화학연구원 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
CN116848117A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN116848118A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171088A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
MX2023012852A (es) 2021-04-29 2024-01-15 Novartis Ag Quimeras que tienen como diana la desubiquitinasa y metodos relacionados.
WO2022228511A1 (zh) 2021-04-30 2022-11-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
CA3211181A1 (en) 2021-05-28 2022-12-01 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Wee1 inhibitor and use thereof
TW202328142A (zh) * 2021-09-18 2023-07-16 香港商優領醫藥科技(香港)有限公司 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
CN118176195A (zh) * 2021-11-01 2024-06-11 正大天晴药业集团股份有限公司 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途
CN116462687B (zh) * 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184A (zh) * 2022-03-25 2023-10-03 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN115073460B (zh) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
WO2024012549A1 (zh) * 2022-07-15 2024-01-18 映恩生物制药（苏州）有限公司 一种嘧啶并五元杂环化合物、其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井製薬工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
ES2137932T3 (es) 1990-09-28 2000-01-01 Smithkline Beecham Corp Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
EP1167384B1 (en) 1992-10-28 2006-12-13 Genentech, Inc. HVEGF Receptor as Vascular endothelial cell growth factor antagonists
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
JP2006504632A (ja) 2002-04-26 2006-02-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー チェックポイントキナーゼ（Ｗｅｅ１およびＣｈｋ１）の阻害剤
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
JP2006518381A (ja) * 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
ES2407811T3 (es) 2004-07-01 2013-06-14 Daiichi Sankyo Company, Limited Derivados de tienopirazol que tienen actividad inhibitoria de PDE 7
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Also Published As

Publication number Publication date
AU2007244185A1 (en) 2007-11-08
KR101409161B1 (ko) 2014-06-19
UA96152C2 (en) 2011-10-10
HRP20161763T1 (hr) 2017-02-24
PT2016080E (pt) 2010-10-14
JP5167291B2 (ja) 2013-03-21
PL2017278T3 (pl) 2017-10-31
SI2016080T1 (sl) 2011-03-31
EP2017278A1 (en) 2009-01-21
MX2008013063A (es) 2008-12-16
PT2017278T (pt) 2017-01-03
US7935708B2 (en) 2011-05-03
GT200800211A (es) 2009-04-07
ATE475662T1 (de) 2010-08-15
HK1132498A1 (en) 2010-02-26
US20140303178A1 (en) 2014-10-09
EP2016080A4 (en) 2009-05-13
TW200811176A (en) 2008-03-01
CN101432284A (zh) 2009-05-13
US20070254892A1 (en) 2007-11-01
PE20080695A1 (es) 2008-06-28
WO2007126122A1 (en) 2007-11-08
US20100063024A1 (en) 2010-03-11
HRP20100563T1 (hr) 2010-11-30
PL2016080T3 (pl) 2011-03-31
DOP2007000084A (es) 2007-12-31
EP2016080A1 (en) 2009-01-21
US20110189130A1 (en) 2011-08-04
BRPI0710081A2 (pt) 2011-08-02
CY1118526T1 (el) 2017-07-12
CA2650119C (en) 2017-03-14
ECSP088812A (es) 2008-11-27
LT2017278T (lt) 2017-01-25
IL194367A (en) 2014-12-31
TWI409262B (zh) 2013-09-21
KR20090017491A (ko) 2009-02-18
ES2609087T3 (es) 2017-04-18
MY145408A (en) 2012-02-15
AU2007244185B2 (en) 2012-10-04
ZA200807748B (en) 2009-10-28
ES2348751T3 (es) 2010-12-13
EP2016080B1 (en) 2010-07-28
DE602007008085D1 (en) 2010-09-09
JP2010132689A (ja) 2010-06-17
CR10359A (es) 2009-02-19
NO341617B1 (no) 2017-12-11
AR060635A1 (es) 2008-07-02
SV2009003060A (es) 2009-04-28
CN101432284B (zh) 2012-08-15
JP4513919B2 (ja) 2010-07-28
US7834019B2 (en) 2010-11-16
JPWO2007126128A1 (ja) 2009-09-17
SI2017278T1 (sl) 2017-05-31
NZ571196A (en) 2011-03-31
MA30428B1 (fr) 2009-05-04
RU2008146759A (ru) 2010-06-10
CA2650119A1 (en) 2007-11-08
EP2017278A4 (en) 2009-04-22
IL194367A0 (en) 2009-08-03
HN2008001532A (es) 2009-06-10
NO20084968L (no) 2008-11-26
US8791125B2 (en) 2014-07-29
EP2017278B1 (en) 2016-11-02
DK2016080T3 (da) 2010-11-22
WO2007126128A1 (ja) 2007-11-08
HUE032987T2 (en) 2017-11-28
RU2437885C2 (ru) 2011-12-27
DK2017278T3 (en) 2017-02-13

Similar Documents

Publication Publication Date Title
CY1111069T1 (el) Παραγωγα διυδροπυραζολοπυριμιδινονης
CY1119882T1 (el) Παραγωγο πυριμιδινης ως αναστολεας ρι3κ και χρηση αυτου
NO20083207L (no) Inhibitorer av IAP
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1111493T1 (el) Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης
CY1115302T1 (el) Ενωση οξαζολιου και φαρμακευτικη συνθεση
CY1122201T1 (el) Παραγωγα βενζοδιοξολιου ως αναστολεις φωσφοδιεστερασης
ATE508747T1 (de) C-kit kinase-hemmer
ATE502038T1 (de) Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
MX2009010595A (es) Derivados de pirrolopirimidina.
CY1115536T1 (el) Νεες υδροξυ-6-ετεροαρυλφαινανθριδινες και χρηση αυτων ως αναστολεις pde4
MX339668B (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.
CY1113486T1 (el) Συντηγμενες δικυκλικες πυριμιδινες
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
UA107689C2 (xx) ПОХІДНІ 3,4,4A,10B-ТЕТРАГІДРО-1H-ТІОПІРАНО$4, 3-c]ІЗОХІНОЛІНУ
NO20076345L (no) Bisykliske derivater som P38-kinaseinhibitorer
ATE478054T1 (de) Benzimidazolderivate
DE602004023271D1 (de) Metastin derivate und ihre verwendung
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA201001348A1 (ru) Пирролопиримидинкарбоксамиды
TW200744603A (en) Novel anticancer concomitant drug
CY1117245T1 (el) Ενωσεις εναντι ογκων